Haleon PLC Sponsored ADR (NYSE:HLN – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $9.78 and traded as low as $8.38. Haleon shares last traded at $8.5550, with a volume of 56,761,965 shares changing hands.
Key Headlines Impacting Haleon
Here are the key news stories impacting Haleon this week:
- Positive Sentiment: Deutsche Bank upgraded Haleon from “sell” to “hold,” removing a bearish recommendation and potentially helping stabilize the stock after its recent decline. Deutsche Bank Haleon recommendations
- Positive Sentiment: Haleon announced a £500 million share buyback, which could support earnings per share and signal that management views the current valuation as attractive. Haleon cuts 2026 forecast and announces buyback
- Neutral Sentiment: Analysts continue to compare Haleon with other consumer-products companies on valuation. The discussion may attract value-focused investors, but it does not provide a major new company-specific catalyst. ASAIY or HLN value stock comparison
- Negative Sentiment: Haleon cut its 2026 organic revenue growth forecast to 2.5% after reporting weaker-than-expected sales. The downgrade raises concerns about slowing demand, pricing pressure and reduced near-term earnings momentum. Haleon cuts 2026 organic revenue forecast
- Negative Sentiment: Chief Executive Brian McNamara warned employees that “difficult choices” may be required following the sales miss, increasing the risk of cost reductions or restructuring. Haleon CEO warns of difficult choices
- Negative Sentiment: Commentary characterized Haleon’s sales performance as a weakness requiring tougher corrective action, reinforcing investor concerns about the company’s growth trajectory. Haleon sales commentary
Wall Street Analyst Weigh In
A number of research firms recently weighed in on HLN. Jefferies Financial Group reaffirmed a “buy” rating on shares of Haleon in a report on Wednesday, September 23rd. Royal Bank Of Canada restated a “sector perform” rating on shares of Haleon in a research report on Tuesday, August 11th. Morgan Stanley restated an “overweight” rating on shares of Haleon in a research note on Thursday, August 6th. Wall Street Zen cut Haleon from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a research report on Friday, September 25th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $4.90.
Check Out Our Latest Report on Haleon
Haleon Stock Performance
The stock has a market cap of $38.14 billion, a price-to-earnings ratio of 22.21, a PEG ratio of 1.93 and a beta of 0.14. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.52 and a current ratio of 0.69. The company’s 50 day simple moving average is $9.54 and its 200 day simple moving average is $9.77.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Third View Private Wealth LLC increased its holdings in shares of Haleon by 4.6% in the 3rd quarter. Third View Private Wealth LLC now owns 431,501 shares of the company’s stock valued at $3,884,000 after purchasing an additional 19,072 shares during the period. Provenance Wealth Advisors LLC boosted its holdings in shares of Haleon by 26,536.3% during the third quarter. Provenance Wealth Advisors LLC now owns 79,909 shares of the company’s stock worth $719,000 after purchasing an additional 79,609 shares during the period. Bank Julius Baer & Co. Ltd Zurich boosted its holdings in shares of Haleon by 4.9% during the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 4,701,182 shares of the company’s stock worth $42,409,000 after purchasing an additional 219,567 shares during the period. Profund Advisors LLC grew its position in Haleon by 12.1% during the third quarter. Profund Advisors LLC now owns 55,100 shares of the company’s stock valued at $496,000 after purchasing an additional 5,929 shares in the last quarter. Finally, Vise Technologies Inc. grew its position in Haleon by 48.0% during the third quarter. Vise Technologies Inc. now owns 79,286 shares of the company’s stock valued at $714,000 after purchasing an additional 25,697 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.
Haleon Company Profile
Haleon plc (NYSE: HLN) is a global consumer health company that develops, manufactures and markets over-the-counter medicines, oral health products, vitamins and supplements. Its portfolio is organized around categories including pain relief, respiratory health, digestive health, therapeutic oral care, everyday oral care, vitamins and minerals, and skin health.
Haleon’s well-known brands include Sensodyne, Polident, parodontax, Centrum, Advil, Voltaren, Panadol, Otrivin and Theraflu. The company’s products are sold through pharmacies, supermarkets, retailers and e-commerce channels, serving consumers in markets around the world.
Haleon was established as an independent consumer health business following its demerger from GSK in July 2022.
Featured Stories
- Five stocks we like better than Haleon
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.
